JAK2 and deep vein thrombosis: JAK2-V617F positive carrier status was also independently associated with two times higher thrombosis incidence during the follow-up of PMF patients irrespective of introduced preventive antithrombotic strategies, and the interaction between JAK2-V617F and leukocytosis further potentiated this effect [69,77].